|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
AU568067B2
(en)
|
1981-10-23 |
1987-12-17 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and methods of making same
|
|
US4476301A
(en)
|
1982-04-29 |
1984-10-09 |
Centre National De La Recherche Scientifique |
Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
|
|
JPS5927900A
(ja)
|
1982-08-09 |
1984-02-14 |
Wakunaga Seiyaku Kk |
固定化オリゴヌクレオチド
|
|
FR2540122B1
(fr)
|
1983-01-27 |
1985-11-29 |
Centre Nat Rech Scient |
Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
|
|
US4605735A
(en)
|
1983-02-14 |
1986-08-12 |
Wakunaga Seiyaku Kabushiki Kaisha |
Oligonucleotide derivatives
|
|
US4948882A
(en)
|
1983-02-22 |
1990-08-14 |
Syngene, Inc. |
Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
|
|
US4824941A
(en)
|
1983-03-10 |
1989-04-25 |
Julian Gordon |
Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
|
|
US4587044A
(en)
|
1983-09-01 |
1986-05-06 |
The Johns Hopkins University |
Linkage of proteins to nucleic acids
|
|
US5118802A
(en)
|
1983-12-20 |
1992-06-02 |
California Institute Of Technology |
DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
|
|
US5550111A
(en)
|
1984-07-11 |
1996-08-27 |
Temple University-Of The Commonwealth System Of Higher Education |
Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
|
|
US5430136A
(en)
|
1984-10-16 |
1995-07-04 |
Chiron Corporation |
Oligonucleotides having selectably cleavable and/or abasic sites
|
|
US5258506A
(en)
|
1984-10-16 |
1993-11-02 |
Chiron Corporation |
Photolabile reagents for incorporation into oligonucleotide chains
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
US4828979A
(en)
|
1984-11-08 |
1989-05-09 |
Life Technologies, Inc. |
Nucleotide analogs for nucleic acid labeling and detection
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
US5235033A
(en)
|
1985-03-15 |
1993-08-10 |
Anti-Gene Development Group |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US5405938A
(en)
|
1989-12-20 |
1995-04-11 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US4762779A
(en)
|
1985-06-13 |
1988-08-09 |
Amgen Inc. |
Compositions and methods for functionalizing nucleic acids
|
|
US4671638A
(en)
|
1985-10-11 |
1987-06-09 |
Eastman Kodak Company |
Moving coil electromagnetic actuator and shutter employing same
|
|
US5317098A
(en)
|
1986-03-17 |
1994-05-31 |
Hiroaki Shizuya |
Non-radioisotope tagging of fragments
|
|
JPS638396A
(ja)
|
1986-06-30 |
1988-01-14 |
Wakunaga Pharmaceut Co Ltd |
ポリ標識化オリゴヌクレオチド誘導体
|
|
EP0260032B1
(en)
|
1986-09-08 |
1994-01-26 |
Ajinomoto Co., Inc. |
Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US4904582A
(en)
|
1987-06-11 |
1990-02-27 |
Synthetic Genetics |
Novel amphiphilic nucleic acid conjugates
|
|
JP2828642B2
(ja)
|
1987-06-24 |
1998-11-25 |
ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン |
ヌクレオシド誘導体
|
|
US5585481A
(en)
|
1987-09-21 |
1996-12-17 |
Gen-Probe Incorporated |
Linking reagents for nucleotide probes
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5525465A
(en)
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
|
DE3738460A1
(de)
|
1987-11-12 |
1989-05-24 |
Max Planck Gesellschaft |
Modifizierte oligonukleotide
|
|
ATE151467T1
(de)
|
1987-11-30 |
1997-04-15 |
Univ Iowa Res Found |
Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
|
|
US5403711A
(en)
|
1987-11-30 |
1995-04-04 |
University Of Iowa Research Foundation |
Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
|
|
US5082830A
(en)
|
1988-02-26 |
1992-01-21 |
Enzo Biochem, Inc. |
End labeled nucleotide probe
|
|
JPH03503894A
(ja)
|
1988-03-25 |
1991-08-29 |
ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション |
オリゴヌクレオチド ｎ‐アルキルホスホラミデート
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5109124A
(en)
|
1988-06-01 |
1992-04-28 |
Biogen, Inc. |
Nucleic acid probe linked to a label having a terminal cysteine
|
|
US5216141A
(en)
|
1988-06-06 |
1993-06-01 |
Benner Steven A |
Oligonucleotide analogs containing sulfur linkages
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US5262536A
(en)
|
1988-09-15 |
1993-11-16 |
E. I. Du Pont De Nemours And Company |
Reagents for the preparation of 5'-tagged oligonucleotides
|
|
US5512439A
(en)
|
1988-11-21 |
1996-04-30 |
Dynal As |
Oligonucleotide-linked magnetic particles and uses thereof
|
|
US5457183A
(en)
|
1989-03-06 |
1995-10-10 |
Board Of Regents, The University Of Texas System |
Hydroxylated texaphyrins
|
|
US5599923A
(en)
|
1989-03-06 |
1997-02-04 |
Board Of Regents, University Of Tx |
Texaphyrin metal complexes having improved functionalization
|
|
US5391723A
(en)
|
1989-05-31 |
1995-02-21 |
Neorx Corporation |
Oligonucleotide conjugates
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
US4958013A
(en)
|
1989-06-06 |
1990-09-18 |
Northwestern University |
Cholesteryl modified oligonucleotides
|
|
US5451463A
(en)
|
1989-08-28 |
1995-09-19 |
Clontech Laboratories, Inc. |
Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5254469A
(en)
|
1989-09-12 |
1993-10-19 |
Eastman Kodak Company |
Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
|
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
|
US5292873A
(en)
|
1989-11-29 |
1994-03-08 |
The Research Foundation Of State University Of New York |
Nucleic acids labeled with naphthoquinone probe
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
US5486603A
(en)
|
1990-01-08 |
1996-01-23 |
Gilead Sciences, Inc. |
Oligonucleotide having enhanced binding affinity
|
|
US5623065A
(en)
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US6395492B1
(en)
|
1990-01-11 |
2002-05-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US6753423B1
(en)
|
1990-01-11 |
2004-06-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
|
US5220007A
(en)
|
1990-02-15 |
1993-06-15 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of RNA and production of encoded polypeptides
|
|
US5214136A
(en)
|
1990-02-20 |
1993-05-25 |
Gilead Sciences, Inc. |
Anthraquinone-derivatives oligonucleotides
|
|
WO1991013080A1
(en)
|
1990-02-20 |
1991-09-05 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
|
DK0455905T3
(da)
|
1990-05-11 |
1998-12-07 |
Microprobe Corp |
Dipsticks til nukleinsyrehybridiseringsassays og fremgangsmåde til kovalent immobilisering af oligonukleotider
|
|
AU8196791A
(en)
|
1990-06-27 |
1992-01-23 |
Trustees Of Columbia University In The City Of New York, The |
Methods for detecting spinal muscular atrophy type i and types ii/iii and marker therefor
|
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5618704A
(en)
|
1990-07-27 |
1997-04-08 |
Isis Pharmacueticals, Inc. |
Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
|
|
US5614617A
(en)
|
1990-07-27 |
1997-03-25 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5677437A
(en)
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5688941A
(en)
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
IL113519A
(en)
|
1990-08-03 |
1997-11-20 |
Sterling Winthrop Inc |
Oligonucleoside sequences of from about 6 to about 200 bases having a three atom internucleoside linkage, their preparation and pharmaceutical compositions for inhibiting gene expression containing said oligonucleosides
|
|
US5245022A
(en)
|
1990-08-03 |
1993-09-14 |
Sterling Drug, Inc. |
Exonuclease resistant terminally substituted oligonucleotides
|
|
US5177196A
(en)
|
1990-08-16 |
1993-01-05 |
Microprobe Corporation |
Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
|
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
|
US5214134A
(en)
|
1990-09-12 |
1993-05-25 |
Sterling Winthrop Inc. |
Process of linking nucleosides with a siloxane bridge
|
|
US5561225A
(en)
|
1990-09-19 |
1996-10-01 |
Southern Research Institute |
Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
|
|
AU662298B2
(en)
|
1990-09-20 |
1995-08-31 |
Gilead Sciences, Inc. |
Modified internucleoside linkages
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
ATE198598T1
(de)
|
1990-11-08 |
2001-01-15 |
Hybridon Inc |
Verbindung von mehrfachreportergruppen auf synthetischen oligonukleotiden
|
|
US5965722A
(en)
|
1991-05-21 |
1999-10-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
WO1994008003A1
(en)
|
1991-06-14 |
1994-04-14 |
Isis Pharmaceuticals, Inc. |
ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
US5371241A
(en)
|
1991-07-19 |
1994-12-06 |
Pharmacia P-L Biochemicals Inc. |
Fluorescein labelled phosphoramidites
|
|
US5571799A
(en)
|
1991-08-12 |
1996-11-05 |
Basco, Ltd. |
(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
|
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
|
US6831166B2
(en)
|
1992-10-23 |
2004-12-14 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
US5700922A
(en)
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
|
US20070032446A1
(en)
|
1991-12-24 |
2007-02-08 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
|
EP0618925B2
(en)
|
1991-12-24 |
2012-04-18 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides
|
|
US5565552A
(en)
|
1992-01-21 |
1996-10-15 |
Pharmacyclics, Inc. |
Method of expanded porphyrin-oligonucleotide conjugate synthesis
|
|
US5595726A
(en)
|
1992-01-21 |
1997-01-21 |
Pharmacyclics, Inc. |
Chromophore probe for detection of nucleic acid
|
|
US5633360A
(en)
|
1992-04-14 |
1997-05-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs capable of passive cell membrane permeation
|
|
US5434257A
(en)
|
1992-06-01 |
1995-07-18 |
Gilead Sciences, Inc. |
Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
|
|
US5272250A
(en)
|
1992-07-10 |
1993-12-21 |
Spielvogel Bernard F |
Boronated phosphoramidate compounds
|
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
|
TW244371B
(cg-RX-API-DMAC7.html)
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
|
JPH08502723A
(ja)
|
1992-07-27 |
1996-03-26 |
ハイブライドン インコーポレイテッド |
オリゴヌクレオチド・アルキルホスホノチオエート
|
|
NZ255578A
(en)
|
1992-09-10 |
1996-11-26 |
Chemo Sero Therapeut Res Inst |
Antisense oligonucleotides complementary and hybridizable to a portion of hepatitis c virus and their use in treating hepatitis c virus associated diseases
|
|
US5574142A
(en)
|
1992-12-15 |
1996-11-12 |
Microprobe Corporation |
Peptide linkers for improved oligonucleotide delivery
|
|
US5605798A
(en)
|
1993-01-07 |
1997-02-25 |
Sequenom, Inc. |
DNA diagnostic based on mass spectrometry
|
|
ES2086997T3
(es)
|
1993-01-25 |
1996-07-01 |
Hybridon Inc |
Oligonucleotido-alquilfosfonatos y -alquilfosfonotioatos.
|
|
US5476925A
(en)
|
1993-02-01 |
1995-12-19 |
Northwestern University |
Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
|
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
|
WO1994022891A1
(en)
|
1993-03-31 |
1994-10-13 |
Sterling Winthrop Inc. |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
|
EP0698092B1
(en)
|
1993-05-11 |
2007-07-25 |
The University Of North Carolina At Chapel Hill |
Antisense oligonucleotides which combat aberrant splicing and methods of using the same
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
US5565350A
(en)
|
1993-12-09 |
1996-10-15 |
Thomas Jefferson University |
Compounds and methods for site directed mutations in eukaryotic cells
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
FR2720757B1
(fr)
|
1994-06-03 |
1996-08-02 |
Inst Nat Sante Rech Med |
Procédé et sondes pour la détection de marqueurs liés au locus des amyotrophies spinales infantiles.
|
|
US5597696A
(en)
|
1994-07-18 |
1997-01-28 |
Becton Dickinson And Company |
Covalent cyanine dye oligonucleotide conjugates
|
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
|
EP0708178A1
(en)
|
1994-10-19 |
1996-04-24 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy
|
|
US6608035B1
(en)
|
1994-10-25 |
2003-08-19 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US5716928A
(en)
|
1995-06-07 |
1998-02-10 |
Avmax, Inc. |
Use of essential oils to increase bioavailability of oral pharmaceutical compounds
|
|
US5652356A
(en)
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
|
US5858401A
(en)
|
1996-01-22 |
1999-01-12 |
Sidmak Laboratories, Inc. |
Pharmaceutical composition for cyclosporines
|
|
CA2246229C
(en)
|
1996-02-14 |
2011-08-23 |
Isis Pharmaceuticals Inc. |
Sugar-modified gapped oligonucleotides
|
|
US6007839A
(en)
|
1996-02-16 |
1999-12-28 |
The Liposome Company, Inc. |
Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
|
|
US6015710A
(en)
|
1996-04-09 |
2000-01-18 |
The University Of Texas System |
Modulation of mammalian telomerase by peptide nucleic acids
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
US6630137B1
(en)
|
1997-04-28 |
2003-10-07 |
Eli Lilly And Company |
Activated protein C formulations
|
|
EP1005327A1
(en)
|
1997-07-02 |
2000-06-07 |
Sdg, Inc. |
Targeted liposomal constructs for diagnostic and therapeutic uses
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
AU4595399A
(en)
|
1998-06-19 |
2000-01-10 |
Mcgill University |
Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
|
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
EP0999270A1
(en)
|
1998-10-09 |
2000-05-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method of regulating SMN gene expression
|
|
US6465628B1
(en)
|
1999-02-04 |
2002-10-15 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
CA2367955C
(en)
|
1999-03-15 |
2009-05-19 |
University Of British Columbia |
Abc1 polypeptide and methods and reagents for modulating cholesterol levels
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
|
CN102180924A
(zh)
|
1999-05-04 |
2011-09-14 |
桑塔里斯制药公司 |
L-核糖-lna类似物
|
|
JP2000325085A
(ja)
|
1999-05-21 |
2000-11-28 |
Masafumi Matsuo |
デュシェンヌ型筋ジストロフィー治療剤
|
|
US20040002153A1
(en)
|
1999-07-21 |
2004-01-01 |
Monia Brett P. |
Modulation of PTEN expression via oligomeric compounds
|
|
US6677445B1
(en)
|
1999-08-27 |
2004-01-13 |
Chiron Corporation |
Chimeric antisense oligonucleotides and cell transfecting formulations thereof
|
|
IL132972A0
(en)
|
1999-11-16 |
2001-03-19 |
Yissum Res Dev Co |
Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
EP1133993A1
(en)
|
2000-03-10 |
2001-09-19 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Substances for the treatment of spinal muscular atrophy
|
|
US6653467B1
(en)
|
2000-04-26 |
2003-11-25 |
Jcr Pharmaceutical Co., Ltd. |
Medicament for treatment of Duchenne muscular dystrophy
|
|
KR20020097241A
(ko)
|
2000-05-04 |
2002-12-31 |
에이브이아이 바이오파마 인코포레이티드 |
스플라이스-영역 안티센스 조성물 및 방법
|
|
WO2001091699A2
(en)
|
2000-05-30 |
2001-12-06 |
Advanced Research & Technology Institute |
Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways
|
|
US6727355B2
(en)
|
2000-08-25 |
2004-04-27 |
Jcr Pharmaceuticals Co., Ltd. |
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
|
|
EP1416972B1
(en)
|
2000-11-09 |
2012-02-08 |
Cold Spring Harbor Laboratory |
Chimeric molecules to modulate gene expression
|
|
WO2002103015A2
(en)
|
2001-06-14 |
2002-12-27 |
Active Pass Pharmaceuticals, Inc. |
Abca10 transporter
|
|
US7407943B2
(en)
*
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
|
US7259150B2
(en)
|
2001-08-07 |
2007-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein (a) expression
|
|
US7060809B2
(en)
|
2001-09-04 |
2006-06-13 |
Exiqon A/S |
LNA compositions and uses thereof
|
|
US20080207542A1
(en)
|
2002-03-26 |
2008-08-28 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
|
US8101348B2
(en)
|
2002-07-10 |
2012-01-24 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
RNA-interference by single-stranded RNA molecules
|
|
US20040219565A1
(en)
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
|
EP2314691A3
(en)
*
|
2002-11-14 |
2012-01-18 |
Dharmacon, Inc. |
Fuctional and hyperfunctional siRNA
|
|
ATE442152T1
(de)
|
2002-11-18 |
2009-09-15 |
Santaris Pharma As |
Antisense-entwurf
|
|
EP2141234B1
(en)
|
2003-03-21 |
2016-04-27 |
Roche Innovation Center Copenhagen A/S |
Short Interfering RNA (siRNA) Analogues
|
|
WO2005001110A2
(en)
|
2003-05-29 |
2005-01-06 |
The Salk Institute For Biological Studies |
Transcriptional regulation of gene expression by small double-stranded modulatory rna
|
|
WO2004113867A2
(en)
|
2003-06-16 |
2004-12-29 |
University Of Massachusetts |
Exon analysis
|
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
|
CA2543013A1
(en)
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of nogo and nogo receptor gene expression using short interfering nucleic acid (sina)
|
|
GB0324854D0
(en)
|
2003-10-24 |
2003-11-26 |
Expresson Biosystems Ltd |
App/ena antisense
|
|
NZ546275A
(en)
|
2003-10-30 |
2009-05-31 |
Coley Pharm Gmbh |
C-class oligonucleotides analogs with enhanced immunostimulatory potency
|
|
CA2566823A1
(en)
|
2003-11-05 |
2005-05-19 |
Board Of Regents, The University Of Texas System |
Diagnostic and therapeutic methods and compositions involving pten and breast cancer
|
|
US7341835B2
(en)
|
2004-01-13 |
2008-03-11 |
Affymetrix, Inc. |
Methods of analysis of alternative splicing in mouse
|
|
AU2005208710A1
(en)
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
|
EP1713912B1
(en)
|
2004-01-30 |
2013-09-18 |
Santaris Pharma A/S |
Modified short interfering rna (modified sirna)
|
|
WO2005089169A2
(en)
|
2004-03-12 |
2005-09-29 |
Exelixis, Inc. |
Mptens as modifiers of the pten pathway and methods of use
|
|
CN101052717A
(zh)
*
|
2004-05-11 |
2007-10-10 |
α基因株式会社 |
诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
|
|
EP2206781B1
(en)
|
2004-06-28 |
2015-12-02 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
US7618947B2
(en)
|
2004-08-25 |
2009-11-17 |
Isis Pharmaceuticals, Inc. |
Modulation of HIF-1 beta expression
|
|
AU2005304110B2
(en)
|
2004-11-09 |
2009-06-11 |
Enzon Pharmaceuticals, Inc. |
LNA oligonucleotides and the treatment of cancer
|
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
|
US9550990B2
(en)
|
2004-12-10 |
2017-01-24 |
Ionis Pharmaceuticals, Inc. |
Regulation of epigenetic control of gene expression
|
|
WO2006069584A2
(en)
|
2004-12-29 |
2006-07-06 |
Exiqon A/S |
NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
|
|
US7879992B2
(en)
|
2005-01-31 |
2011-02-01 |
Isis Pharmaceuticals, Inc. |
Modification of MyD88 splicing using modified oligonucleotides
|
|
EP1855694B1
(en)
|
2005-02-09 |
2020-12-02 |
Sarepta Therapeutics, Inc. |
Antisense composition for treating muscle atrophy
|
|
US20070154896A1
(en)
|
2005-02-11 |
2007-07-05 |
International Business Machines Corporation |
System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences
|
|
WO2006130201A1
(en)
|
2005-03-14 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
Antigene oligomers inhibit transcription
|
|
JP5362350B2
(ja)
|
2005-04-15 |
2013-12-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
小分子活性化ｒｎａ分子及び使用方法
|
|
US8586719B2
(en)
|
2005-04-27 |
2013-11-19 |
Pacific Arrow Limited |
Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents
|
|
PT3308788T
(pt)
|
2005-06-23 |
2019-01-30 |
Cold Spring Harbor Laboratory |
Composições e métodos para a modulação do splicing de smn2
|
|
ES2450593T3
(es)
|
2005-07-01 |
2014-03-25 |
Index Pharmaceuticals Ab |
Método inmunoestimulante
|
|
US8258109B2
(en)
|
2005-10-20 |
2012-09-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of LMNA expression
|
|
DK2641970T3
(en)
|
2005-11-17 |
2015-02-02 |
Univ Texas |
Modulation of gene expression by oligomers targeted to chromosomal DNA
|
|
CN103301475B
(zh)
|
2005-12-28 |
2016-08-03 |
斯克里普斯研究所 |
药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
|
|
US20090011004A1
(en)
|
2005-12-30 |
2009-01-08 |
Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine |
Improved carriers for delivery of nucleic acid agents to cells and tissues
|
|
EP1984499B1
(en)
|
2006-01-27 |
2015-05-27 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of micrornas
|
|
US20100004320A1
(en)
|
2006-04-03 |
2010-01-07 |
Santaris Pharma A/S |
Pharmaceutical Composition
|
|
EA201100813A1
(ru)
|
2006-04-03 |
2012-06-29 |
Сантарис Фарма А/С |
Фармацевтическая композиция
|
|
CN101415726B
(zh)
|
2006-04-07 |
2013-07-31 |
乔治-奥古斯特-哥廷根大学公共利益基金会 |
用于蛋白替代疗法的合成的MeCP2序列
|
|
EP2015758B1
(en)
|
2006-05-05 |
2014-04-02 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression apob
|
|
WO2008025069A1
(en)
|
2006-08-28 |
2008-03-06 |
The Walter And Eliza Hall Institute Of Medical Research |
Methods of modulating cellular activity and compositions therefor
|
|
WO2008029619A1
(fr)
|
2006-09-07 |
2008-03-13 |
Daiichi Sankyo Company, Limited |
Oligonucléotide antisens ena ayant une action spécifique de la séquence
|
|
WO2008036282A1
(en)
|
2006-09-18 |
2008-03-27 |
The Regents Of The University Of Californina |
Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
|
|
US20080139472A1
(en)
|
2006-10-06 |
2008-06-12 |
The Regents Of The University Of California |
Upregulating bdnf levels to mitigate mental retardation
|
|
EP2076597A2
(en)
|
2006-10-09 |
2009-07-08 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of pcsk9
|
|
ES2620472T5
(es)
|
2006-10-18 |
2020-07-09 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
|
JP2010509923A
(ja)
|
2006-11-23 |
2010-04-02 |
ミルクス セラピューティクス アンパーツゼルスカブ |
標的ｒｎａの活性を変化させるためのオリゴヌクレオチド
|
|
EP2118118B1
(en)
|
2007-01-19 |
2017-09-27 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
|
WO2008103761A2
(en)
|
2007-02-20 |
2008-08-28 |
Sequenom, Inc. |
Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation
|
|
US7858592B2
(en)
|
2007-02-26 |
2010-12-28 |
The Board Of Regents Of The University Of Texas System |
Interfering RNAs against the promoter region of P53
|
|
US8580756B2
(en)
|
2007-03-22 |
2013-11-12 |
Santaris Pharma A/S |
Short oligomer antagonist compounds for the modulation of target mRNA
|
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
|
JP2010524486A
(ja)
|
2007-05-01 |
2010-07-22 |
サンタリス ファーマ アー／エス |
β−カテニンを調節するためのＲＮＡアンタゴニスト化合物
|
|
BRPI0811156A2
(pt)
|
2007-05-11 |
2019-09-24 |
Enzon Pharmaceuticals Inc |
compostos antagonistas de rna para a modulação de her3
|
|
JP2010529847A
(ja)
|
2007-06-14 |
2010-09-02 |
ミルクス セラピューティクス アンパーツゼルスカブ |
標的ｒｎａ活性の調節のためのオリゴヌクレオチド
|
|
US20100261175A1
(en)
|
2007-06-15 |
2010-10-14 |
Exiqon A/S |
Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
|
|
US20090082297A1
(en)
|
2007-06-25 |
2009-03-26 |
Lioy Daniel T |
Compositions and Methods for Regulating Gene Expression
|
|
KR20100063048A
(ko)
|
2007-07-31 |
2010-06-10 |
더 존스 홉킨스 유니버시티 |
신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체
|
|
AU2008308499A1
(en)
|
2007-10-04 |
2009-04-09 |
Board Of Regents, The University Of Texas System |
Modulating gene expression with agRNA and gapmers targeting antisense transcripts
|
|
EA019939B1
(ru)
|
2007-10-04 |
2014-07-30 |
Сантарис Фарма А/С |
МОДИФИЦИРОВАННЫЙ ОЛИГОМЕР ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА микроРНК В КЛЕТКЕ
|
|
KR20100105550A
(ko)
|
2007-11-09 |
2010-09-29 |
아이시스 파마수티컬즈 인코포레이티드 |
7 인자 발현 조절
|
|
WO2009064920A2
(en)
|
2007-11-13 |
2009-05-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
|
NZ585327A
(en)
|
2007-11-26 |
2012-10-26 |
Santaris Pharma As |
Lna antagonists targeting the androgen receptor
|
|
US8361980B2
(en)
|
2008-03-07 |
2013-01-29 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microRNA related diseases
|
|
US20110263687A1
(en)
|
2008-04-07 |
2011-10-27 |
Riken |
Rna molecules and uses thereof
|
|
WO2009127680A1
(en)
|
2008-04-16 |
2009-10-22 |
Santaris Pharma A/S |
Pharmaceutical composition comprising anti pcsk9 oligomers
|
|
WO2009134710A2
(en)
|
2008-04-28 |
2009-11-05 |
The Trustees Of The University Of Pennsylvania |
Methods for enhancing utrophin production via inhibition of microrna
|
|
WO2009151546A2
(en)
|
2008-05-27 |
2009-12-17 |
Ptc Therapeutics, Inc. |
Methods for treating spinal muscular atrophy
|
|
EP2297322A1
(en)
|
2008-06-04 |
2011-03-23 |
The Board of Regents of The University of Texas System |
Modulation of gene expression through endogenous small rna targeting of gene promoters
|
|
CA2635187A1
(en)
|
2008-06-05 |
2009-12-05 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Oligonucleotide duplexes and uses thereof
|
|
DK2310505T3
(en)
|
2008-06-30 |
2017-10-16 |
Roche Innovation Ct Copenhagen As |
ANTIDOT oligomers
|
|
WO2010000656A1
(en)
|
2008-07-03 |
2010-01-07 |
Santaris Pharma A/S |
Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1)
|
|
MX2011000601A
(es)
|
2008-07-15 |
2011-03-01 |
Santaris Pharma As |
Antagonistas de acido ribonucleico que con dirigidos a oncogen asociado a glioma 2.
|
|
AU2009276763B2
(en)
|
2008-07-29 |
2015-07-16 |
The Board Of Regents Of The University Of Texas Sytem |
Selective inhibition of polyglutamine protein expression
|
|
US20110237606A1
(en)
|
2008-09-26 |
2011-09-29 |
Agency Of Science, Technology And Research |
3-Deazaneplanocin Derivatives
|
|
CA2739464C
(en)
|
2008-10-03 |
2020-03-31 |
Opko Curna, Llc |
Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
|
|
PE20120115A1
(es)
|
2008-11-17 |
2012-02-20 |
Hoffmann La Roche |
Composiciones y metodos para inhibir la expresion de genes del factor vii
|
|
KR101829469B1
(ko)
|
2008-12-04 |
2018-03-30 |
큐알엔에이, 인크. |
Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
|
|
WO2010065662A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
|
|
EP2370581B1
(en)
|
2008-12-04 |
2016-08-03 |
CuRNA, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
|
WO2010065787A2
(en)
*
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
|
WO2010076248A1
(en)
|
2008-12-31 |
2010-07-08 |
Santaris Pharma A/S |
Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
|
|
WO2010093904A2
(en)
|
2009-02-12 |
2010-08-19 |
Curna, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
CN102439149B
(zh)
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
|
|
WO2010093860A2
(en)
*
|
2009-02-13 |
2010-08-19 |
The General Hospital Corporation |
Isolation of factors that associate directly or indirectly with chromatin
|
|
EP2963116B1
(en)
|
2009-03-04 |
2020-11-11 |
CuRNA, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
|
|
EP2408919B1
(en)
|
2009-03-16 |
2017-10-18 |
CuRNA, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
|
EP2408920B1
(en)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
|
CA2758189C
(en)
|
2009-04-10 |
2020-12-29 |
Association Institut De Myologie |
Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
|
|
WO2010120820A1
(en)
|
2009-04-13 |
2010-10-21 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of smn2 splicing
|
|
ES2599979T3
(es)
|
2009-04-24 |
2017-02-06 |
Roche Innovation Center Copenhagen A/S |
Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
|
|
EP2421972A2
(en)
|
2009-04-24 |
2012-02-29 |
The Board of Regents of The University of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
|
DK2424987T3
(en)
|
2009-05-01 |
2018-02-26 |
Curna Inc |
TREATMENT OF HEMOGLOBIN (HBF / HBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO HBF / HBG
|
|
CN102803492B
(zh)
|
2009-05-06 |
2016-06-29 |
库尔纳公司 |
通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病
|
|
KR101835889B1
(ko)
|
2009-05-06 |
2018-03-08 |
큐알엔에이, 인크. |
지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료
|
|
CN102459597B
(zh)
|
2009-05-08 |
2020-06-30 |
库尔纳公司 |
通过针对dmd家族的天然反义转录物的抑制治疗肌营养蛋白家族相关疾病
|
|
CN102575251B
(zh)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
|
|
US8895527B2
(en)
|
2009-05-22 |
2014-11-25 |
Curna, Inc. |
Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
|
|
CA2764683A1
(en)
|
2009-05-28 |
2010-12-02 |
Joseph Collard |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
|
JP5944311B2
(ja)
|
2009-06-16 |
2016-07-05 |
クルナ・インコーポレーテッド |
コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
|
|
WO2010148065A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
|
AU2010262862C1
(en)
|
2009-06-17 |
2020-04-30 |
Biogen Ma Inc. |
Compositions and methods for modulation of SMN2 splicing in a subject
|
|
WO2010151671A2
(en)
|
2009-06-24 |
2010-12-29 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
|
KR101807324B1
(ko)
|
2009-06-26 |
2017-12-08 |
큐알엔에이, 인크. |
다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
|
|
CN101619312B
(zh)
|
2009-07-10 |
2011-04-20 |
四川大学 |
人黑色素瘤细胞特异表达的长非编码rna序列及其用途
|
|
CN101965029B
(zh)
|
2009-07-21 |
2013-10-02 |
华为终端有限公司 |
支持切换的处理方法、通信装置及通信系统
|
|
KR101801407B1
(ko)
|
2009-07-24 |
2017-11-24 |
큐알엔에이, 인크. |
시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
|
|
KR101802536B1
(ko)
|
2009-08-05 |
2017-11-28 |
큐알엔에이, 인크. |
인슐린 유전자 (ｉｎｓ)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ｉｎｓ) 관련된 질환의 치료
|
|
EP2464731B1
(en)
|
2009-08-11 |
2016-10-05 |
CuRNA, Inc. |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
|
WO2011022606A2
(en)
|
2009-08-21 |
2011-02-24 |
Curna, Inc. |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
|
WO2011025862A2
(en)
|
2009-08-28 |
2011-03-03 |
Curna, Inc. |
Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1
|
|
WO2011032109A1
(en)
|
2009-09-11 |
2011-03-17 |
Sma Foundation |
Biomarkers for spinal muscular atrophy
|
|
WO2011038210A2
(en)
|
2009-09-25 |
2011-03-31 |
Curna, Inc. |
Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
|
|
WO2011038205A2
(en)
|
2009-09-25 |
2011-03-31 |
Curna, Inc. |
Treatment of growth hormone (gh) related diseases by inhibition of natural antisense transcript to gh
|
|
US9364495B2
(en)
|
2009-10-20 |
2016-06-14 |
Roche Innovation Center Copenhagen A/S |
Oral delivery of therapeutically effective LNA oligonucleotides
|
|
KR101138048B1
(ko)
|
2009-11-06 |
2012-04-23 |
성균관대학교산학협력단 |
Ｂｄｎｆ의 발현을 증가시키는 신규 펩타이드 및 이를 포함하는 알츠하이머병 또는 파킨슨병의 예방 및 치료용 약학 조성물
|
|
CA2782366A1
(en)
|
2009-12-16 |
2011-07-14 |
Opko Curna, Llc |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
|
US9068183B2
(en)
|
2009-12-23 |
2015-06-30 |
Curna, Inc. |
Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
|
|
KR101891352B1
(ko)
|
2009-12-23 |
2018-08-24 |
큐알엔에이, 인크. |
간세포 성장 인자(ｈｇｆ)에 대한 천연 안티센스 전사체의 억제에 의한 ｈｇｆ 관련 질환의 치료
|
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
|
RU2016115782A
(ru)
|
2009-12-31 |
2018-11-28 |
Курна, Инк. |
Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3)
|
|
CN102906264B
(zh)
|
2010-01-04 |
2017-08-04 |
库尔纳公司 |
通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
|
|
RU2612161C2
(ru)
|
2010-01-06 |
2017-03-02 |
Курна, Инк. |
Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
|
|
ES2664866T3
(es)
|
2010-01-11 |
2018-04-23 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
|
|
KR101853510B1
(ko)
|
2010-01-25 |
2018-06-20 |
큐알엔에이, 인크. |
Ｒｎａｓｅ ｈ1에 대한 천연 안티센스 전사체의 억제에 의한 ｒｎａｓｅ ｈ1과 관련된 질환의 치료
|
|
WO2011097388A1
(en)
|
2010-02-03 |
2011-08-11 |
Alnylam Pharmaceuticals, Inc. |
Selective inhibition of polyglutamine protein expression
|
|
WO2011097582A2
(en)
|
2010-02-08 |
2011-08-11 |
Opko Curna Llc |
Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b
|
|
US20130059902A1
(en)
|
2010-02-08 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
|
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
|
US20130079505A1
(en)
|
2010-03-24 |
2013-03-28 |
Mirrx Therapeutics A/S |
Bivalent antisense oligonucleotides
|
|
RU2612884C2
(ru)
|
2010-04-02 |
2017-03-13 |
Курна, Инк. |
Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3
|
|
EP3517613A1
(en)
|
2010-04-09 |
2019-07-31 |
CuRNA, Inc. |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
|
US9145556B2
(en)
|
2010-04-13 |
2015-09-29 |
Life Technologies Corporation |
Compositions and methods for inhibition of nucleic acids function
|
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
|
WO2011139387A1
(en)
|
2010-05-03 |
2011-11-10 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
WO2011146674A2
(en)
|
2010-05-19 |
2011-11-24 |
Opko Curna Llc |
Treatment of bcl2-like 11 (bcl2l11) related diseases by inhibition of natural antisense transcript to bcl2l11
|
|
AR081295A1
(es)
|
2010-05-19 |
2012-08-01 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con lim homeobox 2(lhx2) mediante la inhibicion del transcripto antisentido natural a polinucleotidos lhx2
|
|
EP2576783B1
(en)
|
2010-05-26 |
2017-11-29 |
CuRNA, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
|
CA2799596C
(en)
|
2010-05-26 |
2020-09-22 |
Curna, Inc. |
Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
|
|
US9518259B2
(en)
|
2010-06-15 |
2016-12-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating interaction between proteins and target nucleic acids
|
|
US20120004278A1
(en)
|
2010-06-18 |
2012-01-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Linc rnas in cancer diagnosis and treatment
|
|
GB201010557D0
(en)
|
2010-06-23 |
2010-08-11 |
Mina Therapeutics Ltd |
RNA molecules and uses thereof
|
|
PL2585596T3
(pl)
|
2010-06-23 |
2021-06-28 |
Curna, Inc. |
Leczenie chorób związanych z podjednostką alfa kanału sodowego bramkowanego napięciem (SCNA) poprzez hamowanie naturalnego transkryptu antysensownego SCNA
|
|
US20130296316A1
(en)
|
2010-07-09 |
2013-11-07 |
Michael P. Pollastri |
Antiparasitic Agents Based On mTOR Inhibitors
|
|
WO2012009347A2
(en)
|
2010-07-12 |
2012-01-19 |
Opko Curna Llc |
Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3
|
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー，インコーポレイテッド |
Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
|
|
WO2012027033A1
(en)
|
2010-07-19 |
2012-03-01 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals
|
|
KR101900770B1
(ko)
|
2010-07-19 |
2018-09-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법
|
|
WO2012018881A2
(en)
|
2010-08-03 |
2012-02-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for the regulation of rna
|
|
WO2012024478A2
(en)
|
2010-08-19 |
2012-02-23 |
Opko Curna Llc |
Treatment of nicotinamide phosphoribosyltransferase (nampt) related diseases by inhibition of natural antisense transcript to nampt
|
|
KR101235256B1
(ko)
|
2010-09-13 |
2013-02-21 |
서울대학교산학협력단 |
ｍｉＲＮＡ를 타겟으로 한 신경퇴행성 질환 치료
|
|
KR101159456B1
(ko)
|
2010-09-15 |
2012-06-25 |
숭실대학교산학협력단 |
신호 효율이 최대화된 전송선 변압기
|
|
WO2012047956A2
(en)
|
2010-10-06 |
2012-04-12 |
Opko Curna Llc |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
|
WO2012054723A2
(en)
|
2010-10-22 |
2012-04-26 |
Opko Curna Llc |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
|
KR101913232B1
(ko)
|
2010-10-27 |
2018-10-30 |
큐알엔에이, 인크. |
인터페론-관련된 발달성 조절물질 1 (ifrd1)에 대한 자연 안티센스 전사체의 저해에 의한 ifrd1 관련된 질환의 치료
|
|
WO2012087983A1
(en)
|
2010-12-20 |
2012-06-28 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
DK2638163T3
(en)
|
2010-11-12 |
2017-07-24 |
Massachusetts Gen Hospital |
POLYCOMB-ASSOCIATED NON-CODING RNAs
|
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
|
US9145557B2
(en)
|
2010-11-23 |
2015-09-29 |
Mirrx Therapeutics A/S |
Oligonucleotides for modulation of target RNA activity
|
|
WO2012109476A2
(en)
|
2011-02-09 |
2012-08-16 |
The University Of Rochester |
Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements
|
|
WO2012138487A2
(en)
|
2011-04-07 |
2012-10-11 |
The Board Of Regents Of The University Of Texas System |
Oligonucleotide modulation of splicing
|
|
WO2012144220A1
(en)
|
2011-04-22 |
2012-10-26 |
Oncotherapy Science, Inc. |
Ezh2 as target gene for cancer therapy and diagnosis
|
|
US8557787B2
(en)
|
2011-05-13 |
2013-10-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
|
|
WO2012170771A1
(en)
|
2011-06-09 |
2012-12-13 |
Curna, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
|
EP2723864A2
(en)
|
2011-06-23 |
2014-04-30 |
Cold Spring Harbor Laboratory |
Phenocopy model of disease
|
|
US10208305B2
(en)
|
2011-07-05 |
2019-02-19 |
The General Hospital Corporation |
RNA-YY1 interactions
|
|
WO2013036403A1
(en)
|
2011-09-06 |
2013-03-14 |
Curna, Inc. |
TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
|
|
US9580708B2
(en)
|
2011-09-14 |
2017-02-28 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotides compounds
|
|
DE102011083109A1
(de)
|
2011-09-21 |
2013-03-21 |
Wacker Chemie Ag |
Verfahren zur Herstellung von Pulvern aus Alkalisalzen von Silanolen
|
|
US9209196B2
(en)
|
2011-11-30 |
2015-12-08 |
Sharp Kabushiki Kaisha |
Memory circuit, method of driving the same, nonvolatile storage device using the same, and liquid crystal display device
|
|
DK2825648T3
(en)
|
2012-03-15 |
2018-10-15 |
Curna Inc |
TREATMENT OF BRAIN-DERIVATIVE NEUROTROPHIC FACTOR (BDNF) -related DISEASES BY INHIBITATION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
|
|
CN104583401A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节atp2a2表达的组合物和方法
|
|
JP2016528873A
(ja)
|
2012-05-16 |
2016-09-23 |
ラナ セラピューティクス インコーポレイテッド |
遺伝子発現を調節するための組成物及び方法
|
|
WO2013173637A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
|
CA2873779A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating mecp2 expression
|
|
EA201492117A1
(ru)
|
2012-05-16 |
2015-04-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии bdnf
|
|
BR112014028631A2
(pt)
|
2012-05-16 |
2017-10-17 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão da família de genes da hemoglobina
|
|
EP2849801A4
(en)
|
2012-05-16 |
2016-05-25 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHODS FOR MODULATING APOA1 AND ABCA1 EXPRESSION
|
|
EP2850185A4
(en)
|
2012-05-16 |
2015-12-30 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHOD FOR MODULATING UTRN GENE EXPRESSION
|
|
KR20150030205A
(ko)
|
2012-05-16 |
2015-03-19 |
라나 테라퓨틱스, 인크. |
Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
|
|
WO2013173652A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
|
EA201492118A1
(ru)
|
2012-05-16 |
2015-04-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии pten
|
|
US20180312839A1
(en)
|
2015-10-26 |
2018-11-01 |
Translate Bio Ma, Inc. |
Methods and compositions for increasing smn expression
|